Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-025)

NCT04031846 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1184

Enrollment

INDUSTRY

Sponsor class

Conditions

Pneumococcal Infections

Interventions

DRUG: Rotarix™
DRUG: Infanrix™ hexa
DRUG: V114
DRUG: Prevenar 13™

Sponsor

Merck Sharp & Dohme LLC